Please login to the form below
SCLC
This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
EC approves Roche’s Tecentriq for early-stage lung cancer
Tecentriq was the first approved cancer immunotherapy for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy.
Latest news
-
AZ’s Imfinzi combination shows promise in liver cancer
Imfinzi is already used to treat unresectable, stage 3 non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) as well as advanced bladder cancer. ... The company has a broad development programme for Imfinzi plus
-
AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
AstraZeneca has announced that its PD-L1 inhibitor Imfinzi (durvalumab) showed a ‘sustained and clinically meaningful’ survival benefit for patients with extensive stage cell lung cancer (ES-SCLC). ... For treatment purpose, clinicians divide SCLC
-
New data advances AstraZeneca’s “revolution in oncology”
More Imfinzi data will be presented at the European Society for Medical Oncology (ESMO) Congress, showing three-year overall survival data in extensive-stage small cell lung cancer (ES-SCLC), the
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,
-
Roche’s Tecentriq yields positive data in early stage NSCLC
Keytruda has become a new standard-of-care for the treatment of newly-diagnosed NSCLC, although this immunotherapy failed to demonstrate the same benefit in SCLC. ... SCLC is less common than NSCLC but tends to be more aggressive, growing more quickly
More from news
Approximately 6 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
-
Deal Watch November 2015
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
